Skip to main content
. 2020 Sep 18;39(21):e105111. doi: 10.15252/embj.2020105111

Figure EV2. Metformin improves the efficacy of CX‐5461 as a single agent or in combination with Everolimus in vitro .

Figure EV2

  • A
    Propidium iodide (PI) exclusion analysis of Eμ‐Myc lymphoma cells treated with CX‐5461 in the presence and absence of metformin for 48 h. Graphs represent mean ± SEM of n = 3 experiments, and data were analyzed by one‐way ANOVA.
  • B
    PI exclusion analysis of Eμ‐Myc lymphoma cells treated with CX‐5461 + EV in the presence and absence of metformin as indicated for 48 h. Graphs represent mean ± SEM of n = 3 experiments, and data were analyzed by Student's t‐test.
  • C–F
    PI exclusion analysis of (C) MV4‐11, (D) SHI‐1, (E) SKM‐1, and (F) THP‐1 human acute myeloid leukemia cell lines in response to treatments with CX‐5461, everolimus (EV), and metformin as indicated for 72 h. Graphs represent mean ± SEM of n = 4–6, and data were analyzed by two‐way ANOVA.
Data information: ns, not significant, P ≥ 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.Source data are available online for this figure.